Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in BRCA2-altered Prostate Tumors
Open Access
- 17 December 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (6) , 1792-1806
Abstract
Purpose: Alterations in DNA damage repair (DDR) pathway genes occur in 20%–25% of men with metastatic castration-resistant prostate cancer (mCRPC). Although PARP inhibitors (PARPis) have been shown to benefit men with mCRPC harboring DDR defects due to mutations in BRCA1/2 and ATM, additional treatments are necessary because the effects are not durable. Experimental Design: We performed transcriptomic analysis of publicly available mCRPC cases, comparing BRCA2 null with BRCA2 wild-type. We generated BRCA2-null prostate cancer cells using CRISPR/Cas9 and treated these cells with PARPis and SRC inhibitors. We also assessed the antiproliferative effects of combination treatment in 3D prostate cancer organoids. Results: We observed significant enrichment of the SRC signaling pathway in BRCA2-altered mCRPC. BRCA2-null prostate cancer cell lines had increased SRC phosphorylation and higher sensitivity to SRC inhibitors (e.g., dasatinib, bosutinib, and saracatinib) relative to wild-type cells. Combination treatment with PARPis and SRC inhibitors was antiproliferative and had a synergistic effect in BRCA2-null prostate cancer cells, mCRPC organoids, and Trp53/Rb1-null prostate cancer cells. Inhibition of SRC signaling by dasatinib augmented DNA damage in BRCA2-null prostate cancer cells. Moreover, SRC knockdown increased PARPi sensitivity in BRCA2-null prostate cancer cells. Conclusions: This work suggests that SRC activation may be a potential mechanism of PARPi resistance and that treatment with SRC inhibitors may overcome this resistance. Our preclinical study demonstrates that combining PARPis and SRC inhibitors may be a promising therapeutic strategy for patients with BRCA2-null mCRPC.Keywords
All Related Versions
Funding Information
- Department of Defense Prostate Cancer Research (W81XWH1910470)
- Department of Defense Early Investigator Research (W81XWH-18-1-0330)
- NCI (5P01CA228696-02)
- NIH (P30CA008748)
This publication has 68 references indexed in Scilit:
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- Targeting Src family kinases in anti-cancer therapies: turning promise into triumphTrends in Pharmacological Sciences, 2012
- Oncogene-specific activation of tyrosine kinase networks during prostate cancer progressionProceedings of the National Academy of Sciences, 2012
- Role of placenta growth factor in cancer and inflammationExperimental & Molecular Medicine, 2011
- Myristoylation and Membrane Binding Regulate c-Src Stability and Kinase ActivityMolecular and Cellular Biology, 2010
- Latent Bone Metastasis in Breast Cancer Tied to Src-Dependent Survival SignalsCancer Cell, 2009
- ToppGene Suite for gene list enrichment analysis and candidate gene prioritizationNucleic Acids Research, 2009
- Genomic Strategy for Targeting Therapy in Castration-Resistant Prostate CancerJournal of Clinical Oncology, 2009
- Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in boneProceedings of the National Academy of Sciences, 2008